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To the Editor:
The Journal of Thoracic Oncology
has published in its September 2007 issue
a meta-analysis about third-generation
agents in the treatment of advanced non-
small cell lung cancer.1 The authors have
considered the randomized trials pub-
lished until March 2004. Nineteen studies
were selected for the analysis. Some trials
published before 20042–8 were not in-
cluded without very obvious reasons. All
are European authors or publications in
European journals. Vinblastine has to be
considered as one of the active second-
generation drugs, the place of epirubicin
among those is more debatable. In addi-
tion, some important studies have been
published after 2004. It is not clear why
the authors have limited the literature re-
view to March 2004 to perform the meta-
analysis and to publish 3 years later with-
out updating the results.
In addition, a subgroup meta-analy-
sis of the trials comparing third-generation
doublets with second-generation triplets
would probably show no survival differ-
ence as suggested on Figure 5. Two
recently published studies9,10 might be
added to increase the power of the ag-
gregation, although carboplatin has been
used instead of cisplatin. This is an im-
portant question because those types of
triplets are still used in daily practice for
multiple reasons including cost.
Finally, overall survival rather
than 1-year survival should have been
considered, an end point fully possible
in literature-based meta-analyses.
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To the Editor:
We would like to thank Drs. Scu-
lier and Meert for their constructive
criticism of our recent meta-analysis
of third-generation agents in the treat-
ment of advanced non-small cell lung
cancer (NSCLC).1 Their comments re-
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